Drug Database
LE

levonorgestrel (Norplant)

✓ Approved

Takeda · PGR · 小分子

什么是 levonorgestrel?

levonorgestrel 是一种小分子,由Takeda研发。该药已获批,用于治疗相关适应症,给药途径:Surgical Implantation。

药物档案

商品名Norplant
公司Takeda
药物类别小分子
分子靶点PGR
给药途径Surgical Implantation
状态Approved

作用机制

分子靶点

levonorgestrel 作用于 1 个分子靶点:

PGRprogesterone receptor (NR3C3, PR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

相关研究文献

PubMedFP essentials2026-11-16

Menstrual Disorders: Premenopausal Abnormal Uterine Bleeding.

Paruchuri Bindusri B, Miller Amanda A

Abnormal uterine bleeding is a common and distressing concern for reproductive-aged females, potentially leading to long-term consequences such as iron deficiency anemia if not properly addressed. The International Federation of Gynecology and Obstetrics defines abnormal uterine bleeding as bleeding occurring outside the normal frequency of every 24 to 38 days, with additional criteria based on cycle length, regularity, and flow volume. Etiologies are classified using the PALM-COEIN system, which separates structural causes (polyp, adenomyosis, leiomyoma, and malignancy and hyperplasia) from nonstructural causes (coagulopathy, ovulatory dysfunction, endometrial disorders, iatrogenic factors, and conditions not otherwise classified). Transvaginal and transabdominal Doppler ultrasonography are the recommended initial diagnostic modalities for structural etiologies, and magnetic resonance imaging may be used if findings are inconclusive. Endometrial sampling is indicated in patients at increased risk for endometrial pathology, including those with obesity, chronic anovulation, a family history of malignancy, or age of 45 years or older. Management options include medical and surgical therapies. The levonorgestrel-releasing intrauterine system is a highly effective medical treatment, whereas hysterectomy remains the most definitive option, particularly for patients who have completed childbearing. Medical management adequately controls symptoms for many, although structural conditions often require procedural or surgical intervention.

PMID 43037956
阅读全文 →
PubMedJournal of clinical medicine2026-11-14

Advances in Intrauterine Contraception and Therapeutic Intrauterine Devices, 2016-2026: A Targeted Scoping Review.

Biriș Marius M, Buciu Victor Bogdan VB, Cîtu Ioana Mihaela IM, Pescaru Andrei A et al.

Intrauterine contraception has changed over the past decade through longer validated duration, lower-dose hormonal devices, redesigned copper devices, new indications, and better safety surveillance. This targeted scoping review (OSF registration 10.17605/OSF.IO/3GUQF) mapped English-language primary human studies published from 1 January 2016 to 5 September 2026 in journals indexed in the Science Citation Index Expanded (SCIE). A reproducible search targeted to the major device programs, randomized trials, and large surveillance cohorts identified 766 PubMed/MEDLINE records, with no additional unique records from Scopus or Web of Science; of the 624 unique records screened, 123 reports were assessed, and 114, from 66 distinct trials, cohorts, or data sources, were included and appraised with design-specific Joanna Briggs Institute (JBI) tools. Two single-arm programs and a 7-year randomized trial supported the efficacy of 52 mg levonorgestrel intrauterine devices (LNG-IUDs) through 8 years. Lower-dose LNG-IUDs eased placement but were associated with higher ectopic pregnancy rates in four Scandinavian analyses and with less antidepressant use than the 52 mg device. Smaller or size-matched copper devices improved continuation and reduced expulsion in randomized comparisons, whereas a low-copper nitinol device had a higher 5-year pregnancy rate than expected with TCu380A. Perforation was uncommon but more frequent after postpartum insertion and during breastfeeding; immediate postpartum insertion carried the highest expulsion risk. One randomized trial and its secondary analyses supported the 52 mg LNG-IUD for emergency contraception. Therapeutic evidence was strongest for heavy menstrual bleeding and endometrial hyperplasia, whereas intrauterine ball and precious metal designs showed no consistent benefit. Progress refined rather than replaced the T-shaped IUD.

PMID 43030483
阅读全文 →
PubMedThe European journal of contraception & reproductive health care : the official journal of the European Society of Contraception2026-11-13

Technical difficulty of levonorgestrel 52-mg intrauterine device placement and six-month clinical outcomes among women with and without isthmocele: a prospective cohort study.

Laporte Montas M, Marcelino Ana C AC, Juliato Cássia R T CRT, Bahamondes Luis L

To compare pain and difficulty during levonorgestrel 52-mg intrauterine device (LNG 52-mg IUD) insertion in women with and without isthmocele and, secondarily, to assess changes in uterine bleeding, and chronic pelvic pain six months after insertion. Our prospective study was conducted at the Universidade Estadual de Campinas, Brazil. Women aged 18-43 years with at least one caesarean delivery ≥6 months previously, with or without ultrasound-diagnosed isthmocele, were included. Insertion pain, menstrual pain, and chronic pelvic pain were assessed using a 100-mm visual analogue scale (VAS). We included 260 women (103 with and 157 without isthmocele), providing 80% power at α = 0.05 to detect differences in insertion outcomes. Multivariable logistic regression identified factors associated with insertion difficulty and severe pain. Insertion success was similar in women with and without isthmocele (99.0% vs. 98.7%; p = 1.000), as were pain intensity (p = 0.80) and insertion difficulty (p = 0.19). Of 224 women reporting at least one symptom at baseline, 89 (39.7%) had isthmocele and 135 (60.3%) did not. At six months, both groups showed significant reductions in heavy menstrual bleeding, menstrual pain, and chronic pelvic pain (all p < 0.001). Prolonged menstrual bleeding (≥8 days) decreased significantly among women with isthmocele; however, the group-by-time interaction was not significant (p = 0.21). Isthmocele was not associated with greater insertion pain or difficulty. Six months after LNG 52-mg IUD insertion, both groups showed improvements in heavy menstrual bleeding, menstrual pain, and chronic pelvic pain. Isthmocele was not associated with greater insertion pain or difficulty of the LNG 52-mg IUD. Six months after IUD insertion, both groups showed improvements in heavy menstrual bleeding, menstrual pain, and chronic pelvic pain.

PMID 43023222
阅读全文 →
PubMedInternational journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group2026-11-09

Comparison of direct versus hysteroscopy-assisted levonorgestrel intrauterine system placement after high-intensity focused ultrasound ablation for adenomyosis: a retrospective cohort study.

Ding Kun K, Tian Chengzi C, Zhu Qiaoling Q, Sang Changmei C et al.

To compare LNG-IUS stability, clinical outcomes, and safety after direct versus hysteroscopy-assisted placement following high-intensity focused ultrasound (HIFU) ablation for adenomyosis. This single-center retrospective cohort study included 229 premenopausal patients with adenomyosis who underwent HIFU ablation and attempted LNG-IUS placement (direct, n = 135; hysteroscopy-assisted, n = 94). Post-placement outcomes were evaluated among patients with successful first-attempt placement and included LNG-IUS-related events, treatment continuation, symptom scores, lesion volume, and adverse events. Event-free survival was analyzed using Kaplan-Meier and Cox regression, with propensity score matching as a sensitivity analysis. First-attempt placement succeeded in 135 of 135 direct and 91 of 94 hysteroscopy-assisted patients. LNG-IUS-related events were less frequent with hysteroscopy-assisted placement (7.69% vs. 25.93%; p < 0.001), and treatment continuation at last follow-up was higher (92.31% vs. 74.07%; p < 0.001). Event risk remained lower with hysteroscopy-assisted placement before and after adjustment (HR = 0.393, 95% CI 0.173-0.891, p = 0.025; adjusted HR = 0.396, 95% CI 0.158-0.996, p = 0.049). Propensity score matching showed a similar but less precise association (HR = 0.265, 95% CI 0.070-1.002; p = 0.050). Symptom scores and lesion volume decreased in both groups, with no significant between-group difference in adverse events. Hysteroscopy-assisted LNG-IUS placement after HIFU may be associated with fewer displacement or expulsion events and a higher rate of treatment continuation than direct placement. Symptom improvement and recorded adverse events were similar between groups. It may be considered for selected patients with suspected residual intrauterine necrotic tissue or unfavorable uterine cavity conditions.

PMID 43000706
阅读全文 →
PubMedResearch square2026-11-08

Safe Placement of a Micro-Electromechanical Systems (MEMS), Levonorgestrel Releasing Contraceptive: Cadaver and Porcine Studies.

Proos Elizabeth E, Kalish Jeffrey J, Carmine Brian J BJ, Pacelli Nicolas N et al.

In order to develop safe insertion criteria for future clinical studies of a levonorgestrel (LNG) releasing, wirelessly enabled micro-electromechanical system (MEMS)-based drug delivery device, we performed two pre-clinical studies in cadaver arms and pigs. Four female cadaver upper arms were dissected to assess the proposed insertion location, spatial orientation, and proximity to major muscle and neurovascular anatomy. Eight additional cadaver arms were dissected to assess insertion variables (incision depth, width, length, pocket creation). Twenty-four placebo MEMS devices were inserted sub-dermally into the backs of four miniature Yucatan pigs (6 devices per pig). Over a 2-to-4-month postoperative period, wound healing, device migration, and clinical observations were recorded. At removal, tissue capsule quality and tissue adhesions were evaluated. The target medial upper arm insertion site was 8-10 cm proximal to the medial epicondyle toward the axilla and 4-6 cm posterior to the brachial groove. Target insertion width (20 mm), depth (4 mm), and pocket length (51 mm) were defined. Porcine insertions were completed over 6-11 minutes with minimal bleeding. All sites healed well with no device migration over 2-4 months. After removal, tissue capsules were well formed and consistent with the expected normal healing response to a foreign body. These studies confirm the feasibility of safe insertion of the LNG MEMS device in the upper arm and a normal healing response to the device materials in live porcine tissue.

PMID 42996289
阅读全文 →
PubMedOpen access journal of contraception2026-11-03

Impact of Hormonal Contraceptive Exposure on Pancreatic β-Cell Adaptation and Glucose Homeostasis: A Systematic Review.

Niyomugabo Aime Patrick AP, Onaadepo Olufunke O, Ntakirutimana Leopold L, Birhanie Muluken Walle MW et al.

Hormonal contraceptives (HCs) modulate endocrine and metabolic function. Some formulations have been associated with reduced insulin sensitivity, increasing the functional demand on pancreatic β-cells. This systematic review synthesised evidence on pancreatic β-cell adaptation to HC exposure. In accordance with PRISMA 2020, PubMed, Scopus and Wiley Online Library were searched for records published from January 2000 to December 2025, combining terms for β-cell function and adaptation with terms for hormonal contraceptives and for glucose homeostasis and insulin resistance. Eligible studies were original investigations in humans and rodents examining β-cell structural, functional or signalling adaptation to HC exposure, with a comparison group or pre-exposure baseline. Risk of bias was assessed by design using RoB 2, NIH and Newcastle-Ottawa criteria, SYRCLE, and adapted in vitro indicators. Findings were synthesised thematically. Of 502 records identified, seven studies met the criteria: four human, two rodent in vivo and one isolated islet study. In women, ethinylestradiol with norgestimate improved insulin sensitivity in lean participants but reduced it in those with obesity; a drospirenone-containing pill raised HOMA-IR; an oral levonorgestrel preparation reduced insulin sensitivity more than an etonogestrel vaginal ring, with β-cell function unaltered by either; and androgenic formulations amplified postprandial glucose and insulin responses despite unchanged fasting values. In rodents, drospirenone-containing exposure produced hyperinsulinemia with preserved glucose tolerance, attributable to enhanced secretory activity and reduced insulin clearance; levonorgestrel impaired glucose tolerance and raised HOMA-IR, HOMA-β and circulating corticosterone. In isolated rat islets, gestodene metabolites increased insulin and glucokinase expression and glucose-stimulated insulin secretion via oestrogen receptor-dependent pathways. Effects of HC on glucose metabolism and β-cell function appear to depend on progestin composition, route of administration and pre-existing metabolic status. Longitudinal human studies using direct measures of secretory capacity are needed to establish whether compensatory capacity is sustained under continued exposure.

PMID 42974476
阅读全文 →

注册免费账户还可查看另外 5668 篇文献

免费注册查看全部文献 →

了解更多levonorgestrel